Abingdon, United Kingdom

Jean-Francois Pons

USPTO Granted Patents = 5 


Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 21(Granted Patents)


Location History:

  • Abingdon, GB (2008 - 2011)
  • Oxford, GB (2013)

Company Filing History:


Years Active: 2008-2013

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovations of Jean-Francois Pons

Introduction

Jean-Francois Pons is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic compounds. With a total of five patents to his name, Pons has focused on innovative solutions for various medical disorders.

Latest Patents

Pons' latest patents include SirT inhibitors that bind to NAD, specifically a compound of formula (I). These patents describe methods of treating disorders by administering this compound. The disorders targeted by these innovations include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders. Additionally, his patents detail therapeutic compounds that can modulate growth hormone secretagogue receptor (GHS-R), with potential applications in treating obesity.

Career Highlights

Throughout his career, Jean-Francois Pons has worked with prominent companies in the pharmaceutical industry, including Elixir Pharmaceuticals, Inc. and Laboratoires Serono S.A. His work has been instrumental in advancing therapeutic options for patients suffering from various health conditions.

Collaborations

Pons has collaborated with notable professionals in his field, including Jeffrey O. Saunders and Manuel A. Navia. These collaborations have contributed to the development of his innovative patents and have enhanced the impact of his work in the pharmaceutical sector.

Conclusion

Jean-Francois Pons is a distinguished inventor whose work in developing therapeutic compounds has the potential to significantly improve treatment options for various disorders. His contributions to the field are noteworthy and continue to influence the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…